不同亚型1型糖尿病患者大血管病变临床特征及危险因素分析

doi:10.16352/j.issn.1001-6325.2023.08.1284

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (8): 1284-1288.doi: 10.16352/j.issn.1001-6325.2023.08.1284

不同亚型1型糖尿病患者大血管病变临床特征及危险因素分析

王丽婷^1,2#, 许岭翎^1#, 李伟¹, 平凡¹, 张化冰¹, 马亚红^3*, 李玉秀^1*

1.中国医学科学院北京协和医学院北京协和医院内分泌科国家卫生健康委员会内分泌重点实验室,北京 100730;
2.兰州大学第一医院内分泌科,甘肃兰州 730000;
3.北京市普仁医院内分泌科,北京 100062

收稿日期:2022-11-18 修回日期:2023-02-22 出版日期:2023-08-05 发布日期:2023-07-26
通讯作者: ^*liyuxiu@medmail.com; isabella300@126.com
作者简介:^#对本文有相同贡献
基金资助:
中国医学科学院医学与健康科技创新工程项目(2021-12M-C&T-B-003)

Clinical characteristics and risk factors of macrovascular diseases in patients with different subtypes of type 1 diabetes mellitus

WANG Liting^1,2#, XU Lingling^1#, LI Wei¹, PING Fan¹, ZHANG Huabing¹, MA Yahong^3*, LI Yuxiu^1*

1. Department of Endocrinology,Key Laboratory of Endocrinology of National Health Commission,Peking Union Medical College Hospital, CAMS & PUMC, Beijing 100730;
2. Department of Endocrinology, the First Hospital of Lanzhou University,Lanzhou 730000;
3. Department of Endocrinology,Beijing Puren Hospital,Beijing 100062,China

Received:2022-11-18 Revised:2023-02-22 Online:2023-08-05 Published:2023-07-26
Contact: ^*liyuxiu@medmail.com; isabella300@126.com

摘要/Abstract

摘要： 目的探讨不同亚型1型糖尿病(T1DM)患者临床特征以及发生大血管病变的风险。方法回顾性分析2002年3月至2021年7月在北京普仁医院内分泌科就诊的79例T1DM患者的临床资料。其中特发性21例,自身免疫性58例。排除数据缺失者14例,再将其中65例患者分为T1DM大血管病变组(13例)及无大血管病变组(52例)。结果 1)与自身免疫性T1DM患者相比,特发性患者病程长,高密度脂蛋白胆固醇(HDL-c)高,体质量指数(BMI)、糖化血红蛋白(HbA1c)、空腹C肽(FC-P)低。2)与无大血管病变组相比,大血管病变组年龄高,特发性T1DM比例大,肾小球滤过率(eGFR)水平、起病时酮症酸中毒(DKA)发生率更低。3)相关分析显示,大血管病变与年龄、病程呈正相关(r值分别为0.432、0.245,P值均＜0.05),与eGFR、胰岛自身抗体阳性、起病时DKA发生率呈负相关(r值分别为-0.392、-0.268、-0.313,P值均＜0.05)。4)多因素回归分析显示,校正年龄、病程、BMI、eGFR、HDL-c、起病时DKA发生率等混杂因素后,自身抗体阴性是发生大血管病变的危险因素(OR=0.03,95% CI:0.001-0.858,P＜0.05)。结论特发性T1DM患者发生大血管病变的风险较自身免疫性T1DM增加。

关键词: 1型糖尿病, 大血管病变, 特发性, 自身免疫性, 胰岛自身抗体

Abstract: Objective To investigate the clinical characteristics of different subtypes of type 1 diabetes mellitus(T1DM) patients and to analyze the risk of macrovascular diseases in different subtypes of T1DM patients. Methods The clinical data among 79 T1DM patients who treated in the Endocrinology Department of Beijing Puren Hospital from March 2002 to July 2021 were retrospectively analyzed. There were 21 patients with idiopathic T1DM and 58 patients with autoimmune T1DM. Excluding 14 patients because of data missing, 65 patients were divided into macrovascular disease group (n=13) and non-macrovascular disease group (n=52). Results 1)Patients with idiopathic T1DM manifested a longer diabetic course,a higher high density lipoprotein cholesterol(HDL-c)level, a lower body mass index(BMI), hemoglobin A1c(HbA1c) and fasting C peptide(FC-P)level. 2)Compared with the group non-macrovascular disease, the macrovascular disease group was elder with higher prevalence of idiopathic T1DM and lower estimated glomerular filtration rate(eGFR) level and incidence of diabetic ketoacidosis(DKA) at the beginning of disease. 3)Macrovascular lesions were positively correlated with age(r=0.432) and diabetic course (r=0.245)(P＜0.05), were negatively correlated with eGFR(r=-0.392), positive islet autoantibody (r=-0.268) and DKA incidence at the beginning of disease(r=-0.313)(P＜0.05). 4)Multivariate regression analysis showed that negative auto-antibody finding was a risk factor for macrovascular disease (OR=0.03, 95% CI:0.001-0.858, P＜0.05) after age, diabetic course, BMI, eGFR, HDL-c and incidence of DKA at onset were adjusted. Conclusions Patients with idiopathic T1DM show a higher risk of macrovascular disease risk than those with autoimmune T1DM.

Key words: type 1 diabetes mellitus, macrovascular diseases, idiopathic, autoimmunity, islet autoantibody

中图分类号:

R587.1

王丽婷, 许岭翎, 李伟, 平凡, 张化冰, 马亚红, 李玉秀. 不同亚型1型糖尿病患者大血管病变临床特征及危险因素分析[J]. 基础医学与临床, 2023, 43(8): 1284-1288.

WANG Liting, XU Lingling, LI Wei, PING Fan, ZHANG Huabing, MA Yahong, LI Yuxiu. Clinical characteristics and risk factors of macrovascular diseases in patients with different subtypes of type 1 diabetes mellitus[J]. Basic & Clinical Medicine, 2023, 43(8): 1284-1288.

参考文献 12

[1]	Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30-year follow-up[J].Diabetes Care, 2016,39: 686-693.
[2]	Writing Group for the DCCT/EDIC Research Group, Orchard TJ, Nathan DM, et al. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality[J]. JAMA, 2015,313:45-53.
[3]	Tinsley LJ, Kupelian V, D'Eon SA, et al. Association of glycemic control with reduced risk for large-vessel disease after more than 50 years of type 1 diabetes[J]. J Clin Endocrinol Metab, 2017,102:3704-3711.
[4]	中国医师协会内分泌代谢科医师分会, 国家代谢性疾病临床医学研究中心(长沙). 糖尿病分型诊断中国专家共识[J].中国医师杂志,2022,24:161-178.
[5]	中国医师协会内分泌代谢科医师分会. 2型糖尿病早期大血管病变无创性检查的专家共识[J].中国循环杂志,2014,29:167-171.
[6]	Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the european society of hypertension (ESH) and of the european society of cardiology (ESC)[J]. J Hypertens, 2007,25:1105-1187.
[7]	Liu W, Han X, Wang Y, et al. Characteristics and ongoing autoimmunity of patients with long-standing type 1 diabetes living in China[J]. Diabetes Care, 2018,41:e97-e98.
[8]	Secrest AM, Becker DJ, Kelsey SF, et al. All-cause mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes: the Allegheny County type 1 diabetes registry[J]. Diabetes Care, 2010,33:2573-2579.
[9]	Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Risk factors for cardiovascular disease in type 1 diabetes[J]. Diabetes, 2016,65:1370-1379.
[10]	Bebu I, Keshavarzi S, Gao X, et al. Genetic risk factors for CVD in type 1 diabetes: the DCCT/EDIC study[J]. Diabetes Care, 2021,44:1309-1316.
[11]	Catarino D, Silva D, Guiomar J, et al. Non-immune-mediated versus immune-mediated type 1 diabetes: diagnosis and long-term differences-retrospective analysis[J]. Diabetol Metab Syndr, 2020,12:56. doi:10.1186/s13098-020-00563-x.
[12]	Sousa GR, Pober D, Galderisi A, et al. Glycemic control, cardiac autoimmunity, and long-term risk of cardiovascular disease in type 1 diabetes mellitus[J]. Circulation, 2019,139:730-743.

[1]	彭晴怡, 许岭翎. 1型糖尿病诱发肌少症的研究进展[J]. 基础医学与临床, 2024, 44(8): 1189-1193.
[2]	徐云聪, 郑金旭. CD27/CD70与特发性肺纤维化[J]. 基础医学与临床, 2024, 44(8): 1170-1174.
[3]	段然, 李青原, 冯同. 代谢重编程在特发性肺纤维化发病中的作用[J]. 基础医学与临床, 2024, 44(6): 882-886.
[4]	邓娟, 王秀芳, 孙瑞青. 汉黄芩素促进自身免疫性肝炎模型大鼠Th17/Treg细胞平衡[J]. 基础医学与临床, 2024, 44(1): 77-83.
[5]	王春燕, 王萍, 宋龙飞, 刘永全, 满君. LncRNA FEZF1-AS1通过调控EZH2对肺间质细胞增殖、迁移及侵袭的作用[J]. 基础医学与临床, 2024, 44(1): 43-50.
[6]	张忻怡, 赵熙萌, 杨英麦, 万新华, 崔丽英, 张学, 柳青. 特发性震颤患者NOTCH2NLC基因动态突变筛查[J]. 基础医学与临床, 2023, 43(12): 1778-1783.
[7]	李瑜, 张雯, 袁昱, 李姝亭, 王哲, 贲亚琍, 戴飏. 小鼠内源性逆转录病毒Gag抗原在胰岛的表达及单克隆抗体的制备[J]. 基础医学与临床, 2023, 43(1): 59-67.
[8]	文李娜, 陈丽, 段瑞, 李芳. CD8⁺CD25⁺调节性T细胞在疾病中的研究进展[J]. 基础医学与临床, 2022, 42(12): 1939-1944.
[9]	边芳, 李宁, 李奇, 李康, 金雯. 膜联蛋白A1减轻1型糖尿病小鼠微血管并发症[J]. 基础医学与临床, 2021, 41(4): 484-489.
[10]	王慧萍, 崔云英, 马晓森, 文进, 任卫东, 童安莉. 特发性醛固酮增多症的病理分型和手术预后[J]. 基础医学与临床, 2021, 41(10): 1481-1485.
[11]	李倩, 刘纯华, 王晨怡, 谈娇娇, 马玉萍, 吕海宏. 炎性因子调控1型糖尿病血管内皮细胞功能的研究进展[J]. 基础医学与临床, 2021, 41(10): 1497-1501.
[12]	玛依努·玉苏甫, 衣巴地古丽·库吐鲁克, 哈尼克孜·阿不都艾尼. α-硫辛酸对自身免疫性甲状腺炎小鼠炎性反应的抑制作用[J]. 基础医学与临床, 2021, 41(1): 72-76.
[13]	胡苏琴, 王圣凯, 吴杭菲, 郑靖宇, 李剑敏. miR-195抑制剂降低1型糖尿病小鼠肝脏氧化应激损伤[J]. 基础医学与临床, 2020, 40(6): 811-816.
[14]	李佳忆, 幸兵. 免疫检查点抑制剂相关自身免疫性垂体炎的研究进展[J]. 基础医学与临床, 2020, 40(3): 403-406.
[15]	李林林吴聪. 长链非编码RNA 在自身免疫性疾病中的研究进展[J]. 基础医学与临床, 2019, 39(4): 573-576.

不同亚型1型糖尿病患者大血管病变临床特征及危险因素分析

Clinical characteristics and risk factors of macrovascular diseases in patients with different subtypes of type 1 diabetes mellitus

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 12

相关文章 15

编辑推荐

Metrics

本文评价